Dapagliflozin – structure, synthesis, and new indications

Dapagliflozin – structure, synthesis, and new indications

Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitors used in the treatment of patients with type 2 diabetes. An aryl glycoside with significant effect as glucose-lowering agents, Dapagliflozin also has indication for patients with Heart Failure and Chronic Kidney Disease. This revie...

Full description

Bibliographic Details
Main Author: Stefan Balkanski
Format: Article
Language:English
Published: Pensoft Publishers 2021-08-01
Series:Pharmacia
Online Access:https://pharmacia.pensoft.net/article/70626/download/pdf/
id doaj-da7e2fa4fdb84eeca3bf3174fba26112
record_format Article
spelling doaj-da7e2fa4fdb84eeca3bf3174fba261122021-09-29T03:31:44ZengPensoft PublishersPharmacia2603-557X2021-08-0168359159610.3897/pharmacia.68.e7062670626Dapagliflozin – structure, synthesis, and new indicationsStefan Balkanski0Bulgarian Pharmaceutical UnionDapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitors used in the treatment of patients with type 2 diabetes. An aryl glycoside with significant effect as glucose-lowering agents, Dapagliflozin also has indication for patients with Heart Failure and Chronic Kidney Disease. This review examines the structure, synthesis, analysis, structure activity relationship and uses of the product. The studies behind this drug have opened the doors for the new line of treatment – a drug that reduces blood glucoses, decreases the rate of heart failures, and has a positive effect on patients with chronic kidney disease.https://pharmacia.pensoft.net/article/70626/download/pdf/
collection DOAJ
language English
format Article
sources DOAJ
author Stefan Balkanski
spellingShingle Stefan Balkanski
Dapagliflozin – structure, synthesis, and new indications
Pharmacia
author_facet Stefan Balkanski
author_sort Stefan Balkanski
title Dapagliflozin – structure, synthesis, and new indications
title_short Dapagliflozin – structure, synthesis, and new indications
title_full Dapagliflozin – structure, synthesis, and new indications
title_fullStr Dapagliflozin – structure, synthesis, and new indications
title_full_unstemmed Dapagliflozin – structure, synthesis, and new indications
title_sort dapagliflozin – structure, synthesis, and new indications
publisher Pensoft Publishers
series Pharmacia
issn 2603-557X
publishDate 2021-08-01
description Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitors used in the treatment of patients with type 2 diabetes. An aryl glycoside with significant effect as glucose-lowering agents, Dapagliflozin also has indication for patients with Heart Failure and Chronic Kidney Disease. This review examines the structure, synthesis, analysis, structure activity relationship and uses of the product. The studies behind this drug have opened the doors for the new line of treatment – a drug that reduces blood glucoses, decreases the rate of heart failures, and has a positive effect on patients with chronic kidney disease.
url https://pharmacia.pensoft.net/article/70626/download/pdf/
work_keys_str_mv AT stefanbalkanski dapagliflozinstructuresynthesisandnewindications
_version_ 1716865050782728192

Similar Items